Pfizer gets new rebuff from UK cost body for cancer drug
LONDON (Reuters) - Pfizer suffered a second rejection in two days from Britain's health cost watchdog NICE as its new kidney cancer drug Inlyta was turned down for use on the state health service.
The National Institute for Health and Clinical Excellence (NICE) said on Thursday the new treatment was not a cost-effective use of National Health Service resources.
The decision follows a similar rebuff for Pfizer's lung cancer drug Xalkori on Wednesday.
In both cases, the NICE recommendations are preliminary and subject to further consultation.
- Islamic State threat 'beyond anything we've seen': Pentagon
- Oklahoma City policeman arrested for raping women while on patrol
- Ukraine accuses Russia of invasion after aid convoy crosses border |
- Islamic State threat 'beyond anything we've seen': Pentagon |
- Exclusive: Apple iPhone 6 screen snag leaves supply chain scrambling